AMED Insider Trading Activity and SEC Form 4 Filings
AMED insider trading summary
No open-market insider purchases or sales of Amedisys Inc (AMED) have been reported on SEC Form 4 in the past 12 months.
Latest AMED insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 8, 2025 | Allyson Guidroz | Chief Accounting Officer | Sell | $36K (374 @ $96.00) |
| Mar 4, 2025 | Allyson Guidroz | Chief Accounting Officer | Sell | $188K (2,041 @ $92.03) |
| Mar 3, 2023 | Michael Paul North | Chief Information Officer | Sell | $511K (5,908 @ $86.43) |
| Jun 23, 2022 | Denise M. Bohnert | Chief Compliance Officer | Sell | $64K (557 @ $115.00) |
| Mar 29, 2022 | David L Kemmerly | See Remarks | Sell | $4K (20 @ $175.16) |
| Mar 29, 2022 | David L Kemmerly | See Remarks | Sell | $79K (443 @ $177.89) |
| Mar 29, 2022 | David L Kemmerly | See Remarks | Sell | $361K (2,037 @ $177.21) |
| Nov 30, 2021 | Richard A Lechleiter | Director | Buy | $141K (1,000 @ $141.25) |
| Sep 1, 2021 | Bruce D Perkins | Director | Sell | $2.1M (11,511 @ $183.00) |
| Aug 2, 2021 | Christopher Gerard | President & COO | Sell | $117K (450 @ $260.66) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.